Cabozantinib and Lanreotide as Treatment for Gastroenteropancreatic Neuroendocrine Tumors

NCT05048901 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

RECRUITING

Status

49

Enrollment

OTHER

Sponsor class

Conditions

Neuroendocrine Tumors,Gastroenteropancreatic

Interventions

DRUG: Cabozantinib
DRUG: Lanreotide

Sponsor

National Health Research Institutes, Taiwan

Collaborators

[object Object]
[object Object]
[object Object]
[object Object]
[object Object]
[object Object]
[object Object]
[object Object]
[object Object]